RxDoctor Payments Data

Thomas Knox, MD

Cardiovascular Disease · West Hartford, CTNPI 1609838218

Payments from drug & device makers

$8,091in general payments, 2019–2025

Across 420 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Pfizer$934
  • Novartis$846
  • Merck$818
  • E.r. Squibb & Sons, L.L.C.$698
  • AstraZeneca$658
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$7,93598%
  • Education$1562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,091 in reported general payments places this provider in the 75th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$160,604
Medicare patients
1,066
Services billed
2,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban212$215,099
EliquisApixaban157$159,333
EntrestoSacubitril/Valsartan38$36,808
BrilintaTicagrelor40$30,668
JardianceEmpagliflozin23$18,933
FarxigaDapagliflozin Propanediol18$18,298
Praluent PenAlirocumab27$15,253
Ranolazine ErRanolazine64$8,997
Dabigatran EtexilateDabigatran Etexilate Mesylate21$5,675
Metoprolol Succinate306$3,602
Atorvastatin Calcium273$2,055
Ezetimibe61$1,874
Nebivolol Hcl27$1,781
ClopidogrelClopidogrel Bisulfate200$1,780
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,391$215,099212 claims
PfizerEliquis$934$159,333157 claims
AstraZenecaBrilinta, Farxiga$658$48,96758 claims
NovartisEntresto$846$36,80838 claims
Boehringer IngelheimJardiance$343$18,93323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in West Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →